Niagen Bioscience/$NAGE

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Niagen Bioscience

Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.

Ticker

$NAGE
Sector
Primary listing

Employees

104

NAGE Metrics

BasicAdvanced
$554M
32.20
$0.22
2.13
-

What the Analysts think about NAGE

Analyst ratings (Buy, Hold, Sell) for Niagen Bioscience stock.

Bulls say / Bears say

Niagen Bioscience achieved 38% year-over-year net sales growth in Q1 2025, reaching $30.5 million, driven by strong results from both its Tru Niagen consumer supplement and Niagen® ingredient segments. (Nasdaq)
The company became profitable in Q1 2025, reporting net income of $5.1 million and adjusted EBITDA of $4.9 million, with gross margin rising to 63.4%, showing improving operational leverage. (Nasdaq)
In March 2025, Niagen Bioscience expanded its intellectual property portfolio with a new patent covering nicotinamide riboside (NR) salt compositions, strengthening its technological leadership in NAD+ precursor innovation. (Nasdaq)
Q1 2025 net sales were generated exclusively from the Tru Niagen consumer supplement (70.5%) and Niagen® ingredient (26.2%) segments, highlighting limited revenue diversification beyond NAD+ therapies. (Nasdaq)
The company expects general and administrative expenses to increase by $7–8 million in 2025 due to higher share-based compensation, which could put pressure on profitability if revenue growth slows. (Nasdaq)
Niagen Bioscience’s drug development pipeline remains early-stage, as its BIO 2025 participation focused only on starting partnership talks for emerging candidates, indicating limited internal late-stage assets. (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.

NAGE Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

NAGE Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NAGE

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs
Buy Niagen Bioscience stock | $NAGE Share Price | Lightyear